The Diagnosis of Normocalcaemic Hyperparathyroidism is Strikingly Dissimilar Using Different Commercial Laboratory Assays

Abstract

We assessed the impact of intact parathyroid hormone (iPTH) and adjusted calcium analyses on Abbott, Roche and Siemens analytical platforms in the diagnosis of normocalcaemic primary hyperparathyroidism (NCPHPT). These assays are used by over 85% of clinical laboratories in the UK. Over five months, consecutive serum samples from outpatients with NCPHPT in the laboratory with Abbott assays were identified, aliquoted and stored at –80°C. Frozen aliquots were transported monthly to the other two laboratories. After thawing, samples were mixed and analysed immediately for calcium, albumin and iPTH in the laboratories with Abbott, Roche and Siemens analytical platforms. Adjusted calcium was calculated using the equation used in the respective laboratory. Diagnostic concordance of iPTH and adjusted calcium were assessed using manufacturer-provided assay-specific reference intervals and the pathology harmony reference interval respectively. Fifty-five patients with NCPHPT were identified using Abbott assays. Of these, 16 (29.1%) and 11 (20.0%) had NCPHPT, 9 (16.4%) and 13 (23.6%) had hypercalcaemic primary hyperparathyroidism, and 30 (54.6%) and 31 (56.4%) patients had normal results when analysed in laboratories with Roche and Siemens assays, respectively. The diagnosis of NCPHPT was strikingly different depending on the commercial assay used. There is a pressing need for iPTH assay harmonisation and robust reference intervals. Reference intervals may become invalid if an assay drifts, as exemplified by adjusted calcium in this study.

Key words

parathyroid hormone (PTH) - bone/calcium homeostasis - hyperparathyroidism  - parathyroid 

Publication History

Received: 31 January 2022

Accepted after revision: 12 May 2022

Article published online:
14 July 2022

• References

• 1 Bilezikian JP, Khan AA, Potts JT. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94: 335-339
• 2 Eastell R, Brandi ML, Costa AG. et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3570-3579
• 3 Zavatta G, Clarke BL. Normocalcemic hyperparathyroidism: a heterogeneous disorder often misdiagnosed?. JBMR Plus 2020; 4: e10391
• 4 Corbetta S. Normocalcemic hyperparathyroidism. Front Horm Res 2019; 23-39
• 5 Schini M, Jacques RM, Oakes E. et al. Normocalcemic hyperparathyroidism: study of its prevalence and natural history. J Clin Endocrinol Metab 2020; 105: e1171-e1186
• 6 Cusano NE, Maalouf NM, Wang PY. et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 2013; 98: 2734-2741
• 7 García-Martín A, Reyes-García R, Muñoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 2012; 42: 764-766
• 8 Hanon EA, Sturgeon CM, Lamb EJ. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin Chem Lab Med 2013; 51: 1925-1941
• 9 Sturgeon CM, Sprague S, Almond A. et al. Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - a view from the IFCC working group for PTH. Clin Chim Acta 2017; 467: 42-47
• 10 Group KDIGO (KDIGO) C-MUW. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2017; 7: 1-59
• 11 Muntner P, Jones TM, Hyre AD. et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol 2009; 4: 186-194
• 12 Makras P, Polyzos SA, Papatheodorou A. et al. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf) 2013; 79: 499-503
• 13 Cavalier E, Delanaye P, Hubert P. et al. Estimation of the stability of parathyroid hormone when stored at –80°C for a Long Period. Clin J Am Soc Nephrol 2009; 4 1988 LP – 1992
• 14 Cavalier E, Vasikaran S, Bhattoa HP. et al. The path to the standardization of PTH: is this a realistic possibility? a position paper of the IFCC C-BM. Clin Chim Acta 2021; 515: 44-51
• 15 James MT, Zhang J, Lyon AW. et al. Derivation and internal validation of an equation for albumin-adjusted calcium. BMC Clin Pathol 2008; 8: 12
• 16 Barth JH, Fiddy JB, Payne RB. Adjustment of serum total calcium for albumin concentration: effects of non-linearity and of regression differences between laboratories. Ann Clin Biochem 1996; 33: 55-58
• 17 National Institute for Health and Care Excellence(2019). Hyperparathyroidism (primary): diagnosis, assessment and initial management. NICE Guidel [NG132] https//www.nice.org.uk/guidance/ng132 2019
• 18 Berg J, Lane V. Pathology Harmony; a pragmatic and scientific approach to unfounded variation in the clinical laboratory. Ann Clin Biochem 2011; 48: 195-197
• 19 Souberbielle J-C, Brazier F, Piketty M-L. et al. How the reference values for serum parathyroid hormone concentration are (or should be) established?. J Endocrinol Invest 2017; 40: 241-256
• 20 Deckers MML, de Jongh RT, Lips PTAM. et al. Prevalence of vitamin D deficiency and consequences for PTH reference values. Clin Chim Acta 2013; 426: 41-45
• 21 Jassam N, Thomas A, Hayden K. et al. The impact of the analytical performance specifications of calcium and albumin on adjusted calcium. Ann Clin Biochem 2020; 57: 382-388
• 22 Weaving G. Calcium – An adjustment too far or not far enough?. Ann Clin Biochem 2020; 57: 401-403
• 23 Kalaria T, Sanders A, Ford C. et al. Biochemical assessment of adequate Levothyroxine replacement in primary hypothyroidism differs with different TSH assays – potential clinical implications. J Clin Pathol 2021; Online ahead of print
• 24 Cusano NE, Cipriani C, Bilezikian JP. Management of normocalcemic primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab 2018; 32: 837-845
• 25 Silverberg SJ, Clarke BL, Peacock M. et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3580-3594
• 26 Wilhelm SM, Wang TS, Ruan DT. et al. The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016; 151: 959-968